Compare AHL & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AHL | TARS |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.8B |
| IPO Year | 2025 | 2020 |
| Metric | AHL | TARS |
|---|---|---|
| Price | $37.06 | $82.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $39.44 | ★ $76.56 |
| AVG Volume (30 Days) | 234.3K | ★ 518.3K |
| Earning Date | 02-10-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.46 | N/A |
| EPS | ★ 6.60 | N/A |
| Revenue | ★ $3,191,700,000.00 | $366,100,000.00 |
| Revenue This Year | N/A | $147.24 |
| Revenue Next Year | $8.24 | $53.11 |
| P/E Ratio | $5.61 | ★ N/A |
| Revenue Growth | 5.65 | ★ 182.44 |
| 52 Week Low | $27.05 | $38.51 |
| 52 Week High | $37.25 | $85.25 |
| Indicator | AHL | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 56.19 | 59.19 |
| Support Level | $37.05 | $77.14 |
| Resistance Level | $37.25 | $84.07 |
| Average True Range (ATR) | 0.09 | 2.91 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 33.49 | 60.07 |
Aspen Insurance Holdings Ltd is a Bermudian insurance and reinsurance company. Its principal business is marketing and underwriting specialty insurance and reinsurance regularly. It comprises underwriting operations, which include risk-bearing insurance and reinsurance operations; Investing activities, which support underwriting operations; and ACM operations, which earn underwriting, management, and performance fees. It has two segments: Aspen Insurance and Aspen Reinsurance. Aspen Insurance consists of property and casualty insurance, marine, aviation, and energy insurance, and financial and professional lines insurance. Aspen Reinsurance comprises property catastrophe reinsurance, other property reinsurance, casualty reinsurance, and specialty reinsurance.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.